Funder: ALS Association

Due Dates (Anticipated): March 2026 (Letter of Intent) | June 2026 (Full Application by invite)

Funding Amounts: Up to $500,000 total over 2 years (max $250,000/year, incl. direct and indirect costs)

Summary: Supports preclinical assessment of new or repurposed ALS therapies to bridge the gap between academic discovery and clinical drug development.

Key Information: Program is open to both academic and industry researchers; clinical trials and early discovery are not eligible.